Status:
UNKNOWN
To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.
Lead Sponsor:
HoHo Biotech
Conditions:
Autoimmune Diseases
Metabolic Disease
Eligibility:
All Genders
20-70 years
Phase:
PHASE1
Brief Summary
The latest international research shows that supplementation of hydrogen molecules as an aid, adjuvant, can speed up the course of the disease. The purpose of this study is to determine the safety and...
Detailed Description
According to the current literature, there is a lack of specific drugs for chronic inflammatory symptoms which develop from many refractory diseases with complicated clinical features. Hydrogen supple...
Eligibility Criteria
Inclusion
- Age 20 to 70 with autoimmune or metabolic diseases
- Able to compliant with the protocol
- Able to return to the hospital regularly
Exclusion
- Pregnancy
- Expected pregnancy
Key Trial Info
Start Date :
January 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05196295
Start Date
January 11 2022
End Date
July 30 2022
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Min-Sheng Gereral hospital
Taoyuan District, Taiwan